文献速递主动脉疾病

ENGAGE注册研究:Endurant支架系统十年结果

Editor's Choice - The ENGAGE Registry Ten Year Outcomes with the Endurant Stent Graft System for Endovascular Abdominal Aortic Aneurysm Repair.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2025-06-28

延长随访队列5-10年全因死亡免除率97.3%,动脉瘤相关死亡免除率75.7%,转为开放手术免除率99.4%;0-10年动脉瘤破裂免除率96.2%,再干预免除率71.4%。

要点

  • 延长随访队列5-10年动脉瘤相关死亡免除率为75.7%。
  • 0-10年动脉瘤相关再干预免除率为71.4%。
  • 10年时64.1%患者瘤囊回缩,16.8%瘤囊扩张。

核心结论

  • 在ENGAGE注册研究中,入组后存活超过5年的患者接受Endurant支架系统治疗,长期疗效和耐久性总体良好。

研究设计与样本

  • ENGAGE为观察性、多中心、非随机、前瞻性全球注册研究,纳入标准宽松,包括不符合说明书指导的患者。

主要发现

  • 延长随访队列5年至10年,Kaplan-Meier全因死亡免除率为97.3%(95%CI 95.5-99.1%)。
  • 延长随访队列5年至10年,临床事件委员会裁定的动脉瘤相关死亡免除率为75.7%(95%CI 70.4-81.0%)。
  • 延长随访队列5年至10年,转为开放手术修复免除率为99.4%(95%CI 98.6-100%)。
  • 0年至10年,动脉瘤破裂免除率为96.2%(95%CI 94.0-98.4%),动脉瘤相关再干预免除率为71.4%(95%CI 66.3-76.5%)。
  • 延长随访队列前5年,动脉瘤破裂免除率为99.2%(95%CI 98.4-100%),动脉瘤相关再干预免除率为83.6%(95%CI 79.9-87.3%)。

关键数值与推荐

  • 晚期再干预共72例,与Ia型内漏(18/72)、II型内漏(18/72)和Ib型内漏(16/72)相关。
  • 10年时,64.1%患者瘤囊回缩,19.2%瘤囊稳定,16.8%瘤囊扩张。

临床怎么用

  • Endurant支架系统在真实世界腹主动脉瘤患者中显示长期耐久性,支持对存活超过5年的患者持续随访。
  • 晚期再干预与Ia型、II型及Ib型内漏相关,提示长期影像监测内漏的重要性。

局限性

  • 延长随访队列仅390例,为非随机观察性注册研究,可能存在选择偏倚。
  • 纳入标准宽松包括不符合说明书指导的患者,可能影响结果外推。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Long term performance of endovascular aneurysm repair has not been well studied. The Endurant Stent Graft Natural Selection Global Post-market Registry (ENGAGE) observational, multicentre, non-randomised, prospective global registry was used to assess long term outcomes in patients treated with the Endurant stent graft system (Medtronic, Santa Rosa, CA, USA). METHODS: Inclusion criteria were minimal and included patients who fell outside of the instructions for use guidance. Exclusion criteria were high probability of non-adherence to follow up requirements, or concurrent participation in another trial that could confound results. Clinical and imaging data were collected continuously to evaluate treatment efficacy through ten years. RESULTS: There were 1 263 patients enrolled in the ENGAGE registry, of whom 390 re-consented for follow up from more than five through ten years and constituted the extended follow up (FU) cohort. The other 873 patients made up the non-extended FU cohort. For the extended FU cohort from more than five through ten years, Kaplan-Meier rates with 95% confidence intervals (95% CIs) were 97.3% (95% CI 95.5 - 99.1%) for freedom from site reported all cause mortality, 75.7% (95% CI 70.4 - 81.0%) for freedom from Clinical Event Committee adjudicated aneurysm related mortality, and 99.4% (95% CI 98.6 - 100%) for freedom from conversion to open surgical repair. From zero through to ten years, these rates were 96.2% (95% CI 94.0 - 98.4%) for aneurysm rupture and 71.4% (95% CI 66.3 - 76.5%) for aneurysm related re-interventions. For the extended FU cohort in the first five years, freedom estimates were 99.2% (95% CI 98.4 - 100%) for aneurysm rupture and 83.6% (95% CI 79.9 - 87.3%) for aneurysm related re-interventions. Late re-interventions (n = 72) were associated with type Ia endoleaks (18/72), type II endoleaks (18/72), and type Ib endoleaks (16/72). At ten years, 64.1% of patients exhibited sac regression, 19.2% were sac stable, and 16.8% had sac expansion. CONCLUSION: This is the first study to report long term outcomes in a real world, global cohort of patients with abdominal aortic aneurysm treated with the Endurant stent graft. Overall, long term efficacy and durability were observed in patients who survived beyond five years post-enrolment in the ENGAGE registry.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Verhagen HJM, Teijink JAW, Power AH, et al. Editor's Choice - The ENGAGE Registry Ten Year Outcomes with the Endurant Stent Graft System for Endovascular Abdominal Aortic Aneurysm Repair. Eur J Vasc Endovasc Surg. 2025. PMID: 40588161. doi:10.1016/j.ejvs.2025.06.070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。